相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Characterization of kinase inhibitors using different phosphorylation states of colony stimulating factor-1 receptor tyrosine kinase
Daisuke Kitagawa et al.
JOURNAL OF BIOCHEMISTRY (2012)
Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes
Thomas Force et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Expression of the vitamin K-dependent proteins GAS6 and protein S and the TAM receptor tyrosine kinases in human atherosclerotic carotid plaques
Begona Hurtado et al.
THROMBOSIS AND HAEMOSTASIS (2011)
Extended kinase profile and properties of the protein kinase inhibitor nilotinib
Paul W. Manley et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2010)
SIK2 Is a Centrosome Kinase Required for Bipolar Mitotic Spindle Formation that Provides a Potential Target for Therapy in Ovarian Cancer
Ahmed Ashour Ahmed et al.
CANCER CELL (2010)
Cardiac Myosin Light Chain Kinase Is Necessary for Myosin Regulatory Light Chain Phosphorylation and Cardiac Performance in Vivo
Peiguo Ding et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Cardiomyocyte PDGFR-β signaling is an essential component of the mouse cardiac response to load-induced stress
Vishnu Chintalgattu et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Pazopanib
Ronald M. Bukowski et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
The cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity
Brian B. Hasinoff
TOXICOLOGY AND APPLIED PHARMACOLOGY (2010)
A Phase I and Pharmacokinetic Study of Oral Lapatinib Administered Once or Twice Daily in Patients with Solid Malignancies
Howard A. Burris et al.
CLINICAL CANCER RESEARCH (2009)
Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors
George D. Demetri et al.
CLINICAL CANCER RESEARCH (2009)
A Population Pharmacokinetic Meta-analysis of Sunitinib Malate (SU11248) and Its Primary Metabolite (SU12662) in Healthy Volunteers and Oncology Patients
Brett E. Houk et al.
CLINICAL CANCER RESEARCH (2009)
Phase I Trial of Pazopanib in Patients with Advanced Cancer
Herbert I. Hurwitz et al.
CLINICAL CANCER RESEARCH (2009)
Determination of Human Serum alpha(1)-Acid Glycoprotein and Albumin Binding of Various Marketed and Preclinical Kinase Inhibitors
Ferenc Zsila et al.
CURRENT MEDICINAL CHEMISTRY (2009)
KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients
Ketan S. Gajiwala et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Visualization of ATP levels inside single living cells with fluorescence resonance energy transfer-based genetically encoded indicators
Hiromi Imamura et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability
N. Widmer et al.
BRITISH JOURNAL OF CANCER (2008)
c-kit is required for cardiomyocyte terminal differentiation
Ming Li et al.
CIRCULATION RESEARCH (2008)
Nilotinib: a phenylamino-pyrimidine derivative with activity against BCR-ABL, KIT and PDGFR kinases
Alfonso Quintas-Cardama et al.
FUTURE ONCOLOGY (2008)
AMP Activated Protein Kinase-α2 Deficiency Exacerbates Pressure-Overload-Induced Left Ventricular Hypertrophy and Dysfunction in Mice
Ping Zhang et al.
HYPERTENSION (2008)
Heterozygous disruption of Flk-1 receptor leads to myocardial ischaemia reperfusion injury in mice: application of affymetrix gene chip analysis
M. Thirunavukkarasu et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2008)
A quantitative analysis of kinase inhibitor selectivity
Mazen W. Karaman et al.
NATURE BIOTECHNOLOGY (2008)
FDA Drug Approval Summary: Lapatinib in Combination with Capecitabine for Previously Treated Metastatic Breast Cancer That Overexpresses HER-2
Qin Ryan et al.
ONCOLOGIST (2008)
Protein purification and preliminary crystallographic analysis of human Lyn tyrosine kinase
Takayoshi Kinoshita et al.
PROTEIN EXPRESSION AND PURIFICATION (2008)
In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib
Jamshid S. Khorashad et al.
BLOOD (2008)
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases
Oleg Fedorov et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
The selectivity of protein kinase inhibitors: a further update
Jenny Bain et al.
BIOCHEMICAL JOURNAL (2007)
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
Tammy F. Chu et al.
LANCET (2007)
Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia
Deborah White et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia
Pier Paolo Piccaluga et al.
CANCER (2007)
Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors
Marcus Bantscheff et al.
NATURE BIOTECHNOLOGY (2007)
The 2.7 Å crystal structure of the autoinhibited human c-Fms kinase domain
Mark Walter et al.
JOURNAL OF MOLECULAR BIOLOGY (2007)
Approval summary: Sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma
Vicki L. Goodman et al.
CLINICAL CANCER RESEARCH (2007)
Food and drug administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma
Edwin P. Rock et al.
ONCOLOGIST (2007)
Targeted therapy for metastatic renal cell carcinoma
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
Scott Wilhelm et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL
E. Weisberg et al.
BRITISH JOURNAL OF CANCER (2006)
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Features of selective kinase inhibitors
ZA Knight et al.
CHEMISTRY & BIOLOGY (2005)
Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours
A Awada et al.
BRITISH JOURNAL OF CANCER (2005)
A small molecule-kinase interaction map for clinical kinase inhibitors
MA Fabian et al.
NATURE BIOTECHNOLOGY (2005)
Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor
AR Tan et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Discovery of N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays
LJ Lombardo et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
The specificities of protein kinase inhibitors: an update
J Bain et al.
BIOCHEMICAL JOURNAL (2003)
Discovery of 5-[5-Fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase
L Sun et al.
JOURNAL OF MEDICINAL CHEMISTRY (2003)
FDA drug approval summary: Gefitinib (ZD1839) (Iressa (R)) tablets
MH Cohen et al.
ONCOLOGIST (2003)
The protein kinase complement of the human genome
G Manning et al.
SCIENCE (2002)
A scaleable synthesis of BAY 43-9006: A potent Raf kinase inhibitor for the treatment of cancer
D Bankston et al.
ORGANIC PROCESS RESEARCH & DEVELOPMENT (2002)
Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: Results of a phase I trial
RS Herbst et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Protein kinases - the major drug targets of the twenty-first century?
P Cohen
NATURE REVIEWS DRUG DISCOVERY (2002)
The role of protein phosphorylation in human health and disease - Delivered on June 30th 2001 at the FEBS Meeting in Lisbon
P Cohen
EUROPEAN JOURNAL OF BIOCHEMISTRY (2001)
Specificity and mechanism of action of some commonly used protein kinase inhibitors
SP Davies et al.
BIOCHEMICAL JOURNAL (2000)
Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase
T Schindler et al.
SCIENCE (2000)
分享论文
